NeuroVoices: Michael Levy, MD, PhD, on Comparing Patient Outcomes of Inebilizumab and Rituximab in NMOSD
Neurology Live,
Michael Levy, MD, PhD (Credit: The Sumaira Foundation) Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune…
Michael Levy, MD, PhD (Credit: The Sumaira Foundation) Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune…
In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of…
WATCH TIME: 4 minutes "These new drugs are remarkably effective, scientifically proven, and offer reduced risks, making them…
WATCH TIME: 4 minutes "What surprised us is that there were quite a few relapses in the rituximab group, pretty similar to the…